Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment (Q34074094)

30 July 2017

title

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

1

Peter A Fasching

1 reference

30 July 2017

16

Matthias W Beckmann

1 reference

30 July 2017

12

Michael P Lux

1 reference

30 July 2017

14

Arndt Hartmann

1 reference

30 July 2017

2

Katharina Heusinger

1 reference

30 July 2017

3

Lothar Haeberle

1 reference

30 July 2017

6

Christian M Bayer

1 reference

30 July 2017

10

Michael Schrauder

1 reference

30 July 2017

Melitta Niklos

4

1 reference

30 July 2017

Alexander Hein

5

1 reference

30 July 2017

Claudia Rauh

7

1 reference

30 July 2017

Ruediger Schulz-Wendtland

8

1 reference

30 July 2017

Mayada R Bani

9

1 reference

30 July 2017

Laura Kahmann

11

1 reference

30 July 2017

Johanna D Strehl

13

1 reference

30 July 2017

Arno Dimmler

15

1 reference

30 July 2017

David L Wachter

17

1 reference

30 July 2017

language of work or name

English

0 references

publication date

14 November 2011

1 reference

30 July 2017

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

page(s)

486

1 reference

Personalized treatment of early-stage breast cancer: present concepts and future directions

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

Ki67 in breast cancer: prognostic and predictive potential

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3262864

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-486

Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22081974

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22081974

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22081974

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-11-486

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference